Q-omics provides the consensus-scored ZNF22-AS1 profile across patient tissues and cancer cell-line models. ZNF22-AS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF22-AS1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ZNF22-AS1 RNA expression shows 18,288 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where ZNF22-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF22-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF22-AS1 survival associations across molecular data types. ZNF22-AS1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF22-AS1 RNA expression–survival associations across cancer types. High ZNF22-AS1 expression shows unfavorable associations in STAD, LIHC, BLCA and MESO, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF22-AS1 RNA expression.
This table summarizes ZNF22-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF22-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF22-AS1 shows lower tumor expression in THCA, LUAD, LUSC and KICH and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher ZNF22-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.827, t-test p < 0.001).
This table shows molecular features associated with ZNF22-AS1 in patient tissues and cancer cell lines. In patient samples, ZNF22-AS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF22-AS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
